Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mayo Clinic researchers make anti-cancer virus discovery
In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a
In the process of making cancer-killing viruses more specific to cancer tumor cells, they report having improved the therapeutic effectiveness of viruses. They did this by engineering a
Antibodies developed under the contract will protect US citizens against the harmful effects of botulinum neurotoxins used in bioterrorism. This award follows a $15 million contract with the
FluMist is currently approved in the US to prevent influenza in individuals five to 49 years of age. MedImmune is seeking to gain approval for the refrigerator-stable formulation
Insegia, also known as G17DT, is a therapeutic cancer vaccine that has been extensively studied for its effects on cancers of gastrointestinal (GI) origin. The immunotherapeutic stimulates the
Under the terms of the agreement, Predix and Amgen will collaborate on the development of existing Predix preclinical compounds and new S1P1 modulators. Amgen will be responsible for
Zileuton CR is an investigational drug for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. Critical Therapeutics currently markets
Ankylosing spondylitis (AS), an autoimmune disease affecting the spine and large peripheral joints, is the third of six autoimmune diseases targeted for Humira (adalimumab) therapy that has received
In the study, mature male rats immunized with specific types of the active vaccine ate normally yet gained less weight and had less body fat, indicating that the
The FDA has approved Synovics’ abbreviated new drug application (ANDA) for a generic version of metformin extended release (XR) tablets 500mg. Bristol-Myers Squibb markets the therapeutically equivalent listed
Drawing upon its drug discovery chemistry expertise, Tripos Discovery Research (TDR), which is based in Bude, England, has entered into an extension of its previous chemistry research contract